tetano
Editor, Senior Moderator
J Epidemiol Glob Health
. 2023 Feb 16.
doi: 10.1007/s44197-023-00090-8. Online ahead of print.
COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates
Nihar Ranjan Dash[SUP] 1 [/SUP], Hiba Jawdat Barqawi[SUP] 2 [/SUP], Anas A Obaideen[SUP] 3 [/SUP], Hanae Qousae Al Chame[SUP] 3 [/SUP], Kamel A Samara[SUP] 3 [/SUP], Rama Qadri[SUP] 3 [/SUP], Salma Eldesouki[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Despite significant efforts to contain the Coronavirus Disease 2019 (COVID-19) pandemic through mass vaccination, numerous nations throughout the world have recorded breakout infections. The incidence and severity of COVID-19 breakthrough infections in the United Arab Emirates (UAE) remain unknown despite extensive COVID-19 vaccine coverage. The goal of this research is to establish the characteristics of COVID-19 breakthrough infections in the UAE's vaccinated population.
Methods: Between February and March 2022, we conducted a descriptive cross-sectional study in the UAE with 1533 participants to examine the characteristics of COVID-19 breakthrough infection among the vaccinated population.
Results: The vaccination coverage was 97.97%, and the COVID-19 breakthrough infection rate was 32.1%, requiring hospitalization in 7.7% of cases. The bulk of the 492 COVID-19 breakthrough infections reported was among young adults (67%), with the majority experiencing mild to moderate symptoms (70.7%) or remaining asymptomatic (21.5%).
Conclusions: COVID-19 breakthrough infection were reported in younger age, male sex, non-healthcare professions, vaccination with inactivated whole virus vaccine (Sinopharm), and not receiving a booster dose. Information on breakthrough infection in the UAE might influence public health decisions and motivate measures such as providing additional booster doses of the vaccines to the people.
Keywords: Breakthrough infections; COVID-19; Covid vaccine; Pfizer-BioNTech; Sinopharm BBIBP-CorV; UAE.
. 2023 Feb 16.
doi: 10.1007/s44197-023-00090-8. Online ahead of print.
COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates
Nihar Ranjan Dash[SUP] 1 [/SUP], Hiba Jawdat Barqawi[SUP] 2 [/SUP], Anas A Obaideen[SUP] 3 [/SUP], Hanae Qousae Al Chame[SUP] 3 [/SUP], Kamel A Samara[SUP] 3 [/SUP], Rama Qadri[SUP] 3 [/SUP], Salma Eldesouki[SUP] 3 [/SUP]
Affiliations
- PMID: 36795274
- DOI: 10.1007/s44197-023-00090-8
Abstract
Background: Despite significant efforts to contain the Coronavirus Disease 2019 (COVID-19) pandemic through mass vaccination, numerous nations throughout the world have recorded breakout infections. The incidence and severity of COVID-19 breakthrough infections in the United Arab Emirates (UAE) remain unknown despite extensive COVID-19 vaccine coverage. The goal of this research is to establish the characteristics of COVID-19 breakthrough infections in the UAE's vaccinated population.
Methods: Between February and March 2022, we conducted a descriptive cross-sectional study in the UAE with 1533 participants to examine the characteristics of COVID-19 breakthrough infection among the vaccinated population.
Results: The vaccination coverage was 97.97%, and the COVID-19 breakthrough infection rate was 32.1%, requiring hospitalization in 7.7% of cases. The bulk of the 492 COVID-19 breakthrough infections reported was among young adults (67%), with the majority experiencing mild to moderate symptoms (70.7%) or remaining asymptomatic (21.5%).
Conclusions: COVID-19 breakthrough infection were reported in younger age, male sex, non-healthcare professions, vaccination with inactivated whole virus vaccine (Sinopharm), and not receiving a booster dose. Information on breakthrough infection in the UAE might influence public health decisions and motivate measures such as providing additional booster doses of the vaccines to the people.
Keywords: Breakthrough infections; COVID-19; Covid vaccine; Pfizer-BioNTech; Sinopharm BBIBP-CorV; UAE.